☰

Eneda Toska, Ph.D. - Publications

Affiliations: 
2013 Biological Sciences State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Human Development, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Blawski R, Toska E. A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer. Cancer Research. 82: 3668-3670. PMID 36245246 DOI: 10.1158/0008-5472.CAN-22-2594  0.324
2022 Ladewig E, Michelini F, Jhaveri K, Castel P, Carmona J, Fairchild L, Zuniga AG, Arruabarrena-Aristorena A, Cocco E, Blawski R, Kittane S, Zhang Y, Sallaku M, Baldino L, Hristidis V, ... ... Toska E, et al. The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation. Cancer Research. PMID 35442400 DOI: 10.1158/0008-5472.CAN-22-0446  0.387
2021 Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Kim SE. UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34330832 DOI: 10.1073/pnas.2103592118  0.302
2021 Loats AE, Carrera S, Fleming AF, Roberts ARE, Sherrard A, Toska E, Moorhouse AJ, Medler KF, Roberts SGE. Cholesterol is required for transcriptional repression by BASP1. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34266955 DOI: 10.1073/pnas.2101671118  0.626
2020 Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S, Ferrando L, Cocco E, Ho SY, Tan DS, Sallaku M, Wu F, Acevedo B, ... ... Toska E, et al. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell. PMID 32888433 DOI: 10.1016/J.Ccell.2020.08.003  0.396
2020 Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, ... ... Toska E, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics. PMID 31932695 DOI: 10.1038/S41588-019-0554-0  0.417
2020 Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. PMID 31915197 DOI: 10.1158/2159-8290.Cd-19-0116  0.424
2020 Vasan N, Razavi P, Johnson JL, Shao H, Wilson T, Schimmoller F, Shah H, Antoine A, Ladewig E, Gorelick A, Lin T, Toska E, Xu G, Kazmi A, Chang MT, et al. Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-03-01  0.358
2020 Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, et al. Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors Cancer Research. 80: 5680-5680. DOI: 10.1158/1538-7445.Am2020-5680  0.319
2019 Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: x3-x11. PMID 31859348 DOI: 10.1093/Annonc/Mdz281  0.33
2019 Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, et al. Double mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.). 366: 714-723. PMID 31699932 DOI: 10.1126/Science.Aaw9032  0.347
2019 Castel P, Toska E. Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer. Molecular & Cellular Oncology. 6: e1625620. PMID 31692833 DOI: 10.1080/23723556.2019.1625620  0.407
2019 Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. PMID 31406350 DOI: 10.1038/S41591-019-0542-Z  0.375
2019 Toska E, Castel P, Chhangawala S, Arruabarrena-Aristorena A, Chan C, Hristidis VC, Cocco E, Sallaku M, Xu G, Park J, Minuesa G, Shifman SG, Socci ND, Koche R, Leslie CS, et al. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell Reports. 27: 294-306.e5. PMID 30943409 DOI: 10.1016/J.Celrep.2019.02.111  0.51
2019 Toska E, Xu G, Chhangawala S, Cocco E, Razavi P, Otto J, Cai Y, Chan C, Avino DRD, Collings C, Levine RL, Scaltriti M, Reis-Filho JS, Kadoch C, Leslie C, et al. Abstract 949: ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-949  0.324
2019 Cocco E, Kulick A, Misale S, Yaeger R, Razavi P, Won HH, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, et al. Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-118  0.357
2019 Ladewig E, Fairchild L, Scaltriti M, Leslie C, Toska E, Baselga J. Abstract 4346: PI3K pathway mediated splicing defects in ER+ breast cancers Cancer Research. 79: 4346-4346. DOI: 10.1158/1538-7445.Am2019-4346  0.431
2019 Vasan N, Razavi P, Johnson J, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, et al. Abstract 3917: DoublePIK3CAmutations incisenhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer Cancer Research. 79: 3917-3917. DOI: 10.1158/1538-7445.Am2019-3917  0.367
2018 Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling. 11. PMID 30301790 DOI: 10.1126/Scisignal.Aat9773  0.307
2017 Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 2: e90196. PMID 28352655 DOI: 10.1172/Jci.Insight.90196  0.415
2017 Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science (New York, N.Y.). 355: 1324-1330. PMID 28336670 DOI: 10.1126/Science.Aah6893  0.455
2017 Osmanbeyoglu HU, Toska E, Chan C, Baselga J, Leslie CS. Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. Nature Communications. 8: 14249. PMID 28139702 DOI: 10.1038/Ncomms14249  0.481
2016 Perovic V, Sumonja N, Gemovic B, Toska E, Roberts SG, Veljkovic N. TRI_tool: a web-tool for prediction of protein protein interactions in human transcriptional regulation. Bioinformatics (Oxford, England). PMID 27605104 DOI: 10.1093/Bioinformatics/Btw590  0.59
2016 Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell. PMID 27451907 DOI: 10.1016/J.Ccell.2016.06.004  0.365
2016 Toska E, Baselga J. Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 2099-101. PMID 26957555 DOI: 10.1158/1078-0432.Ccr-16-0038  0.303
2016 Toska E, Osmanbeyoglu H, Elkabets M, Chan C, Castel P, Dickler M, Armstrong S, Leslie C, Scaltriti M, José B. Abstract 885: Epigenetic regulation of estrogen receptor transcription by the PI3K pathway in breast cancer Cancer Research. 76: 885-885. DOI: 10.1158/1538-7445.Am2016-885  0.479
2016 Osmanbeyoglu HU, Toska E, Baselga J, Leslie C. Abstract 781: Modeling the impact of somatic alterations across human cancers Cancer Research. 76: 781-781. DOI: 10.1158/1538-7445.Am2016-781  0.408
2016 Castel P, Ellis H, Bago R, Toska E, Srinivasaraghavan K, Carmona FJ, Razavi P, Verma C, Dickler M, Chandarlapaty S, Brogi E, Alessi D, Baselga J, Scaltriti M. Abstract 2107: PDK1 blockade overcomes intrinsic resistance to PI3Kα inhibition Cancer Research. 76: 2107-2107. DOI: 10.1158/1538-7445.Am2016-2107  0.429
2015 Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science Translational Medicine. 7: 283ra51. PMID 25877889 DOI: 10.1126/Scitranslmed.Aaa4442  0.443
2014 Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M. Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular & Cellular Oncology. 1: e963447. PMID 27308344 DOI: 10.4161/23723548.2014.963447  0.315
2014 Shandilya J, Toska E, Richard DJ, Medler KF, Roberts SG. WT1 interacts with MAD2 and regulates mitotic checkpoint function. Nature Communications. 5: 4903. PMID 25232865 DOI: 10.1038/Ncomms5903  0.73
2014 Toska E, Roberts SG. Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). The Biochemical Journal. 461: 15-32. PMID 24927120 DOI: 10.1042/Bj20131587  0.692
2014 Gao Y, Toska E, Denmon D, Roberts SG, Medler KF. WT1 regulates the development of the posterior taste field. Development (Cambridge, England). 141: 2271-8. PMID 24803588 DOI: 10.1242/Dev.105676  0.63
2014 Busch M, Schwindt H, Brandt A, Beier M, Görldt N, Romaniuk P, Toska E, Roberts S, Royer HD, Royer-Pokora B. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation. Human Molecular Genetics. 23: 3958-74. PMID 24619359 DOI: 10.1093/Hmg/Ddu111  0.644
2014 Toska E, Shandilya J, Goodfellow SJ, Medler KF, Roberts SG. Prohibitin is required for transcriptional repression by the WT1-BASP1 complex. Oncogene. 33: 5100-8. PMID 24166496 DOI: 10.1038/Onc.2013.447  0.749
2014 Dolma K, Iacobucci GJ, Hong Zheng K, Shandilya J, Toska E, White JA, Spina E, Gunawardena S. Presenilin influences glycogen synthase kinase-3 β (GSK-3β) for kinesin-1 and dynein function during axonal transport. Human Molecular Genetics. 23: 1121-33. PMID 24105467 DOI: 10.1093/Hmg/Ddt505  0.649
2014 Toska E, Elkabets M, Bosch A, Litvin O, Scaltriti M, Baselga J. 71 Novel regulation of estrogen receptor transcription by the PI3K pathway European Journal of Cancer. 50: 28. DOI: 10.1016/S0959-8049(14)70197-2  0.428
2012 Toska E, Campbell HA, Shandilya J, Goodfellow SJ, Shore P, Medler KF, Roberts SG. Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell Reports. 2: 462-9. PMID 22939983 DOI: 10.1016/J.Celrep.2012.08.005  0.746
2011 Goodfellow SJ, Rebello MR, Toska E, Zeef LA, Rudd SG, Medler KF, Roberts SG. WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line. The Biochemical Journal. 435: 113-25. PMID 21269271 DOI: 10.1042/Bj20101734  0.657
Show low-probability matches.